Project name: Innitius
EU Contribution: € 3 800 000
Location: Spain
Innitius develops CerviSense, a CE-marked diagnostic platform that measures cervical stiffness using torsional wave elastography and AI. It allows clinicians to detect risk of preterm labor, failed inductions, and false labor earlier and more accurately. By reducing diagnostic uncertainty, it improves outcomes for mothers and babies, prevents unnecessary interventions, and brings advanced, accessible maternal care to both high-resource and underserved health systems.
Vision & ImpactCerviSense is transforming maternal health by offering the first objective, biomechanical method to detect risk in pregnancy. By reducing diagnostic uncertainty, it helps prevent preterm births, avoid unnecessary interventions, and bring equity to women’s care globally.
CollaborationThe EIC Accelerator has been a turning point in our journey. It enabled us to launch our pivotal clinical trials, scale production, and unlock cross-border partnerships. Beyond funding, it gave us trust, visibility, and a European platform to drive systemic change in obstetric care.
What's next ?We are expanding CerviSense across Europe with leading hospitals, launching pilots in Africa to address maternal health inequities, and initiating FDA steps for U.S. approval. Our next goal is to embed CerviSense as a standard tool in global pregnancy risk management.
The EIC support is helping us build a world where preterm birth no longer begins with guesswork. Thanks to this program, CerviSense is already in hospitals protecting mothers and babies. The EIC didn’t just fund innovation — it helped us reshape the clinical standard for safer pregnancies worldwide.
Innitius' Timeline
- 2027 (planned)
– European certification of the threatened preterm labor indication, expanding clinical impact in high-risk pregnancies
- 2025
– €2.3M EIC Accelerator grant awarded, recognising the breakthrough potential and societal impact of the technology
– European certification of the hardware platform, enabling structured deployment in hospitals
– Manufacturing scale-up and commercial readiness achieved - 2024
– €3M growth round closed to accelerate clinical programme and prepare market entry
- 2023
– Multicenter clinical validation expanded, strengthening evidence across different hospital environments
- 2022
– First official clinical trial completed (91 pregnant women), demonstrating high reproducibility and reliability
– Proprietary artificial intelligence tool developed to translate biomechanical data into clinical decision support
– Core patents filed, securing protection of the underlying technology - 2021
– €1.5M Seed Round closed, enabling transition from research to structured product development
– Quality management system certified, establishing industrial-grade processes and compliance - 2020
– Technology validated in 128 patients, confirming robust diagnostic performance and clinical feasibility
- 2018
– First clinical prototype completed, introducing a novel biomechanical approach to cervical assessment